BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q2 2023 vs. Q1 2023
How the institutions holding BIO-TECHNE Corp changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 552 | 4 | 529 | −19 |
| Shares | 148.8M | 117.4K | 151.2M | +2.49M (+1.7%) |
| Value | $11.0B | $8.71M | $12.3B | +$1.30B (+11.8%) |
4 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (53)
Institutions that held BIO-TECHNE Corp at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (72)
Institutions that held BIO-TECHNE Corp at the end of Q1 2023 and filed for Q2 2023 without it.
Not filed for Q2 2023 yet (4)
Institutions that held BIO-TECHNE Corp at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Fithian, LLC | 101,020 | $7.49M |
| Avalon Investment & Advisory | 9,716 | $720.8K |
| ETF Managers Group, LLC | 6,679 | $495.5K |
| Ahrens Investment Partners LLC | 28 | $2.08K |